MST-0312
Solid Tumors
Pre-clinicalActive
Key Facts
About Mestag Therapeutics
Mestag Therapeutics is an early-stage biotech pioneering a novel approach in immunotherapy by targeting activated fibroblasts, a key but historically overlooked component of the tumor microenvironment and inflammatory disease sites. The company's lead asset, MST-0312, is a bispecific antibody in pre-clinical development aimed at inducing tertiary lymphoid structures (TLS) in solid tumors to enhance immune attack. A second program, M402, is developing agonist antibodies to inhibit fibroblast-driven inflammation in conditions like rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and lupus. Based in Cambridge, UK, Mestag is a private company rapidly advancing its portfolio toward the clinic.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| DM001 | Domabio | Phase 1 |
| DM002 | Domabio | Phase 1 |
| DM005 | Domabio | Phase 1 |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| CAR-T Solid Tumor Program | Carina Biotech | Phase 1/2a |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |